SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
AmeriLithium Corp. (OTCBB: AMEL) $0.90. Announced Monday that Cohen Independent Research Group, Inc. announced that it has updated its coverage on AmeriLithium Corp. (AMEL) a lithium exploration and mining company head-quartered in Nevada. The updated report was issued with a target price of $4.73, up from $3.63 in the previous report.
The Cohen research report stated that Lithium (Li) is one of the fastest emerging sources of clean energy. The demand for lithium is expected to grow manifold due to its diverse application and environmental friendly impact. The Company intends to capitalize on this emerging market opportunity with the acquisition of 723,969 acres of exploration properties. The Company has already started utilizing the $10 million equity drawdown facility. AmeriLithium announced acquisition of two more properties in Nevada, USA, Clayton Deep and Full Monty. Initial tests conducted on these properties by US Geological Survey have yielded significant mineral deposit estimates.
What They Do: AmeriLithium Corp. (AMEL) is a lithium exploration and mining company . The Company primarily targets the automobile sector which is experiencing a paradigm shift towards non-fossil fuel based cars. AMEL remains focused on expanding through strategic acquisition of properties with rich mineralization prospects. The Company has acquired exploration lands of approximately 723,969 acres, which includes two Nevada-based projects in the US, one project in Alberta, Canada and 3 projects in Western Australia.
Kinetic Concepts (NYSE: KCI) $41.34. Today announced it has received 510(k) clearance from the Food and Drug Administration for the Prevena Incision Management System, a negative pressure wound therapy product designed for management of surgically closed incisions. KCI estimates more than three million procedures are performed each year worldwide that could benefit from treatment with the Prevena System, representing a potential global opportunity greater than $1 billion. The product will be available to hospitals in the U.S. in early July.
“KCI’s focus is on developing new technologies that improve patients’ lives, something we have done again with the launch of the Prevena System,” said Catherine Burzik, KCI’s president and CEO. “It’s another important milestone as we continue to execute on our growth strategy of commercializing a highly differentiated portfolio of products that help improve clinical outcomes and deliver tangible cost benefits.”
What They Do: Kinetic Concepts is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets.
Abbott (NYSE: ABT) $48.17 and Neurocrine Biosciences (Nasdaq: NBIX) $4.70. Today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
"Extensive preclinical and clinical experience with elagolix suggests this drug could be an important advance for women with endometriosis and uterine fibroids, highly prevalent conditions where there is a need for new treatments," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott. "This agreement enhances Abbott's late stage pipeline, with the potential for additional compounds in earlier stage development."
Under the terms of the agreement, Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women's and men's health. Abbott will make an upfront payment of $75 million and will fund all ongoing development activities. Neurocrine is eligible to receive additional milestone payments of approximately $500 million from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future product sales.
What They Do: Neurocrine Biosciences is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview. SmallCapReview has been compensated seven thousand five hundred dollars for its efforts with regards to AmeriLithium by a third party AWT.
